Contents

Search

selinexor (Xpovio)

Indications: - for use in combination with dexamethasone for treatment of adults with relapsed/refractory multiple myeloma* * at least four prior therapies, resistant to other forms of treatment, including at least two proteasome inhibitors, at least two immunomodulatory agents, & an anti-CD38 monoclonal antibody [2] Dosage: - 20 mg tablets - 60, 80, 100 mg weekly Monitor: - complete blood count (CBC) - serum sodium Adverse effects: - leukopenia, neutropenia, thrombocytopenia, anemia - nausea/vomiting, diarrhea, constipation, decreased appetite, weight loss - fatigue, fever, - upper respiratory tract infections - hyponatremia.

General

neurologic agent

References

  1. RxNorm
  2. Mulcahy N FDA Approves Selinexor for Refractory Multiple Myeloma. Medscape - Jul 03, 2019. https://www.medscape.com/viewarticle/915213